Novavax, Inc.
FSX: NVV1.F0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Frankfurt Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- John Charles Jacobs
- Employees
- 952
- Headquarters
- Gaithersburg, United States
- IPO year
- 2001
- Market cap
- €1.4B
- Website
- https://www.novavax.com
Loading NVV1…
Loading profile data…Frequently asked questions about NVV1
What does Novavax, Inc. (NVV1.F) do?
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...
Where does NVV1.F trade?
Novavax, Inc. (NVV1.F) trades on the Frankfurt Stock Exchange.
What sector is NVV1.F in?
Novavax, Inc. (NVV1.F) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Novavax, Inc.?
John Charles Jacobs is the chief executive officer of Novavax, Inc. (NVV1.F).
Where is Novavax, Inc. headquartered?
Novavax, Inc. is headquartered in United States.
Does NVV1.F pay a dividend?
Novavax, Inc. (NVV1.F) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did NVV1.F go public?
Novavax, Inc. (NVV1.F) completed its initial public offering in 2001.